Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B15e1e7fd895c6a8e8dc43f2dbc96f7b7> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B15e1e7fd895c6a8e8dc43f2dbc96f7b7 NCIT_P378 "NCI" @default.
- B15e1e7fd895c6a8e8dc43f2dbc96f7b7 type Axiom @default.
- B15e1e7fd895c6a8e8dc43f2dbc96f7b7 annotatedProperty IAO_0000115 @default.
- B15e1e7fd895c6a8e8dc43f2dbc96f7b7 annotatedSource NCIT_C107191 @default.
- B15e1e7fd895c6a8e8dc43f2dbc96f7b7 annotatedTarget "Autologous human T-lymphocytes transduced with a retroviral vector encoding an anti-epidermal growth factor receptor (EGFR) chimeric T cell receptor (chimeric antigen receptor or CAR) gene coupled to the signaling domains from both CD3 zeta and CD137 (4-1BB), with potential immunostimulatory and antineoplastic activities. Upon administration, the chimeric EGFR antigen receptor-modified autologous T lymphocytes bind to the EGFR antigen on tumor cell surfaces; subsequently, EGFR-expressing tumor cells may be lysed. Following binding to EGFR, the 4-1BB co-stimulatory molecule signaling domain enhances both activation and signaling. Inclusion of the 4-1BB signaling domain may also increase the antitumor activity when compared to the inclusion of the CD3-zeta chain alone. EGFR, a receptor tyrosine kinase (RTK) overexpressed by a variety of cancer cell types, plays key roles in tumor cell proliferation and tumor angiogenesis." @default.